-

Dxcover to Present New Data on Liquid Biopsy Platform at the 2023 American Association for Cancer Research (AACR) Annual Meeting

GLASGOW, Scotland--(BUSINESS WIRE)--Dxcover Limited, a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, today announced the upcoming presentation of new data on its liquid biopsy platform at the 2023 American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida from April 14-19. The poster presentation will outline data from a preclinical study evaluating the Dxcover® Cancer Liquid Biopsy platform’s capabilities to detect advanced adenomas and early cases of colorectal cancer.

“The future of cancer care will depend on reliable and comprehensive methods to detect malignancies earlier, enabling easier treatment and lower rates of recurrence for patients,” said Matthew J. Baker, Ph.D., co-founder and Chief Technical Officer of Dxcover. “Dxcover’s proprietary liquid biopsy technology combines novel infrared spectroscopy with artificial intelligence in order to rapidly detect cancers with ideal specificity and sensitivity, and I look forward to sharing the latest data on our platform’s potential to detect cancers early.”

Presentation details:

Title: Early colorectal cancer detection with a spectroscopic liquid biopsy
Abstract Number: 6506
Session Title: Early Detection and Molecular Markers of Prevention
Session Date and Time: Wednesday Apr 19, 2023 9:00 AM - 12:30 PM
Location: Orange County Convention Center, Poster Section 28

About Dxcover Limited
Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer by infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is expanding its network in Europe and the USA.

For further information go to https://www.dxcover.com/science

Contacts

Dxcover Limited


Release Versions

Contacts

More News From Dxcover Limited

Dxcover Announces Three New Clinical Trials for Brain, Colorectal and Lung Cancer Detection

GLASGOW, Scotland--(BUSINESS WIRE)--Dxcover Limited, a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer. The company has launched its EMBRACE study, a 2,200-patient trial focused on the early detection of brain cancer. Dxcover® Brain Cancer is a...

Dxcover To Present at BIOTECH SHOWCASE™ 2024

GLASGOW, Scotland--(BUSINESS WIRE)--Dxcover Limited, a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, today announced that Founder and newly announced CEO Matthew Baker, PhD, will be presenting at Biotech Showcase 2024. Prof. Baker will be presenting data from the company’s clinical studies in early detection of solid tumors. Dxcover’s novel platform utilizes infrared spectroscopy and AI algorithms to provide Multi-Omic Spectr...

Dxcover Announces Updates to Executive Leadership Team

GLASGOW, Scotland--(BUSINESS WIRE)--Dxcover Limited, a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, today announced updates to its executive management team. Dxcover’s Co-Founder Prof. Matthew Baker will transition from his role as Chief Technical Officer to Chief Executive Officer. Another Co-Founder Dr David Palmer, who has been Chief Data Scientist since spin-out, has been named Chief Technical Officer. Current CEO Dr Mar...
Back to Newsroom